home / stock / oryzf / oryzf quote
Last: | $1.41 |
---|---|
Change Percent: | 0.0% |
Open: | $1.41 |
Close: | $1.41 |
High: | $1.41 |
Low: | $1.41 |
Volume: | 300 |
Last Trade Date Time: | 04/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.41 | $1.41 | $1.41 | $1.41 | $1.41 | 300 | 04-16-2024 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 300 | 03-13-2024 |
$2 | $2.25 | $2 | $2.25 | $2 | 12,000 | 02-07-2024 |
$1.8 | $2.1 | $1.8 | $2.1 | $1.8 | 5,000 | 01-09-2024 |
$1.77 | $2.26 | $1.77 | $2.26 | $1.77 | 5,000 | 01-08-2024 |
$1.7 | $1.7 | $1.7 | $1.7 | $1.7 | 2,000 | 11-24-2023 |
$2.22 | $2.22 | $2.22 | $2.22 | $2.22 | 750 | 09-05-2023 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 245 | 05-31-2023 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 204 | 03-29-2023 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 750 | 03-14-2023 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 100 | 04-27-2022 |
$2.77 | $2.77 | $2.77 | $2.77 | $2.77 | 100 | 03-08-2022 |
$2.77 | $2.77 | $2.77 | $2.77 | $2.77 | 100 | 01-24-2022 |
$4.13 | $4.13 | $4.13 | $4.13 | $4.13 | 5,000 | 07-26-2021 |
$4.36 | $4.36 | $4.36 | $4.36 | $4.36 | 100 | 07-12-2021 |
$4.67 | $4.67 | $4.67 | $4.67 | $4.67 | 200 | 06-28-2021 |
$4.77 | $4.77 | $4.77 | $4.77 | $4.77 | 300 | 06-18-2021 |
$4.18 | $4.18 | $4.18 | $4.18 | $4.18 | 4,000 | 05-06-2021 |
$4.15 | $4.15 | $4.15 | $4.15 | $4.15 | 300 | 05-05-2021 |
$4.6 | $4.6 | $4.6 | $4.6 | $4.6 | 1,000 | 03-11-2021 |
News, Short Squeeze, Breakout and More Instantly...
Oryzon Genomics S.A. Company Name:
ORYZF Stock Symbol:
OTCMKTS Market:
All resolutions were approved Additional resolution to increase capital for up to 100 million euros approved 42.6867% of the issued shares represented MADRID and CAMBRIDGE, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a c...
Selected for oral presentation Conference will be held in Milan on September 21-23 MADRID and CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop th...
Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed strong antileukemic activity A third cohort is ongoing following FDA’s OPTIMUS guidance MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon G...